A Comparison of 141W94 and Indinavir in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used
with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also
examines what effect other drugs have on how the body handles 141W94.
Phase:
Phase 3
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Amprenavir HIV Protease Inhibitors Indinavir Protease Inhibitors Reverse Transcriptase Inhibitors